Drug Type Antibody fusion proteins |
Synonyms CMX-02 |
Target |
Mechanism IL-23 inhibitors(Interleukin-23 inhibitors), TNF-α inhibitors(Tumor necrosis factor α inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Autoimmune Diseases | Preclinical | BE | - |